Addus Homecare Corp SEC Filings

Addus HomeCare Corp (ADUS) submitted a Form 144 notifying a proposed sale of 9,000 common shares to be executed through Morgan Stanley Smith Barney LLC on NASDAQ approximately 08/13/2025. The filing lists an aggregate market value of $1,038,105.90 and 18,407,239 shares outstanding, implying a per-share value near $115.35 and the sale representing about 0.05% of outstanding shares.

All 9,000 shares were issued as restricted stock across grants dated 03/01/2022, 02/23/2024, 02/24/2024 and 02/24/2025. The filing reports no securities sold in the past three months and includes the seller's certification that they are not aware of undisclosed material adverse information. The document provided does not identify the individual seller or include additional issuer contact details in the visible fields.

Addus HomeCare Corp. Schedule 13G reports that Capital Research Global Investors (CRGI) beneficially owns 1,102,298 shares of common stock, equal to 6.0% of the 18,399,139 shares reported outstanding. CRGI is described as a division of Capital Research and Management Company and related investment management entities and is deemed the beneficial owner through those entities. The filing states CRGI has sole voting power and sole dispositive power over all 1,102,298 shares and no shared powers. The filing certifies the securities are held in the ordinary course of business and not to influence control. SMALLCAP World Fund, Inc. is identified as an account referenced in the filing.

Wasatch Advisors LP reports beneficial ownership of 929,154 shares of Addus HomeCare common stock, representing 5.1% of the class. That level of ownership triggers Schedule 13G/A disclosure and identifies Wasatch as a material institutional holder of Addus HomeCare.

The filing states Wasatch has sole dispositive power over all 929,154 shares and sole voting power over 690,487 shares, with no shared voting or dispositive power. The document classifies Wasatch as an investment adviser organized in Delaware and includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

Esteban Lopez, a director of Addus HomeCare (ADUS), sold 522 shares of common stock on 08/08/2025 at $109 per share. After the sale he beneficially owns 4,016 shares held directly. The filing reports only this non-derivative sale, shows no derivative holdings, and does not disclose a 10b5-1 trading plan. The Form 4 was executed by an attorney-in-fact.

Addus HomeCare (ADUS) filed a Form 144 reporting a proposed resale of 522 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $56,898 and 18,407,239 shares outstanding. The filing lists an approximate sale date of 08/08/2025.

The securities were acquired as restricted stock from the issuer on 06/12/2025 with payment recorded the same day, and the filer reports "Nothing to Report" for sales in the past three months. This Form 144 is a notice of intended resale under Rule 144 and includes the seller's representation that they are not aware of any undisclosed material adverse information.

Addus HomeCare Corporation (ADUS) reported the voting results from its 18 June 2025 Annual Meeting of Stockholders in an 8-K filing (Item 5.07).

• Quorum: 17,431,919 shares (94.7% of the 18,399,139 shares outstanding) were represented.
• Director elections: Class I nominees Esteban López, M.D. (93.2% support), Jean Rush (95.2% support) and Susan T. Weaver, M.D. (91.5% support) were elected for terms expiring in 2028. Broker non-votes totaled 875,876 for each nominee.
• Auditor ratification: PricewaterhouseCoopers LLP was re-appointed with 17,369,357 votes for (99.7%), 59,873 against and 2,689 abstentions.
• Say-on-Pay: Executive compensation received 15,216,859 votes for (92.0%), 1,330,522 against and 8,662 abstentions.
• Say-on-Pay frequency: An annual vote was favored by 15,903,154 shares (92.9%), compared with 632,362 for triennial, 3,984 for biennial and 16,543 abstentions. No broker non-votes.
• Board response: The Board will continue to hold the advisory Say-on-Pay vote annually until the next required frequency vote.

The filing contains no financial performance data, strategic transactions or changes to previously reported guidance. All proposals were approved by wide margins, indicating solid shareholder support for governance, compensation and audit practices.